ZEB1‐mediated melanoma cell plasticity enhances resistance to MAPK inhibitors

Targeted therapies with MAPK inhibitors (MAPKi) are faced with severe problems of resistance in BRAF‐mutant melanoma. In parallel to the acquisition of genetic mutations, melanoma cells may also adapt to the drugs through phenotype switching. The ZEB1 transcription factor, a known inducer of EMT and...

Descripción completa

Detalles Bibliográficos
Autores principales: Richard, Geoffrey, Dalle, Stéphane, Monet, Marie‐Ambre, Ligier, Maud, Boespflug, Amélie, Pommier, Roxane M, de la Fouchardière, Arnaud, Perier‐Muzet, Marie, Depaepe, Lauriane, Barnault, Romain, Tondeur, Garance, Ansieau, Stéphane, Thomas, Emilie, Bertolotto, Corine, Ballotti, Robert, Mourah, Samia, Battistella, Maxime, Lebbé, Céleste, Thomas, Luc, Puisieux, Alain, Caramel, Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5048365/
https://www.ncbi.nlm.nih.gov/pubmed/27596438
http://dx.doi.org/10.15252/emmm.201505971

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5048365/
https://www.ncbi.nlm.nih.gov/pubmed/27596438
http://dx.doi.org/10.15252/emmm.201505971

Ejemplares similares